1. Home
  2. Stocks
  3. Auropharma Share Price
  • Chart
  • F&O
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs

    • Aurobindo Pharma Share Price

    Large Cap
    ₹1,552.45
    -11.55 (-0.74%)
    • Advice
    • Hold
    18 September, 2024 02:47 BSE: 524804 NSE: AUROPHARMA ISIN: INE406A01037

    Start SIP in Aurobindo Pharma

    Start SIP

    Aurobindo Pharma Performance

    Day Range

    • Low 1,549
    • High 1,568
    ₹ 1,552

    52 Week Range

    • Low 835
    • High 1,592
    ₹ 1,552
    • Open Price1,564
    • Previous Close1,564
    • Volume584857

    Aurobindo Pharma Chart

    • Over 1 Month + 3.31%
    • Over 3 Month + 23.31%
    • Over 6 Month + 55.04%
    • Over 1 Year + 72.72%

    Aurobindo Pharma Key Statistics

    P/E Ratio 25.8
    PEG Ratio 0.3
    Market Cap Cr
    Price to Book Ratio 3
    EPS 33.3
    Dividend 0.3
    Relative Strength Index 59.72
    Money Flow Index 44.78
    MACD Signal 29.8
    Average True Range 35.39

    Aurobindo Pharma F&O

    Aurobindo Pharma Futures Aurobindo Pharma Option Chain

    Aurobindo Pharma Investment Rating

    • Master Rating:

    • Aurobindo Pharma has an operating revenue of Rs. 29,718.37 Cr. on a trailing 12-month basis. An annual revenue growth of 18% is outstanding, Pre-tax margin of 15% is great, ROE of 10% is good. The company has a reasonable debt to equity of 7%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 8% and 31% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 72 which is a FAIR score but needs to improve its earnings, a RS Rating of 72 which is FAIR indicating the recent price performance, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 59 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock definitely has some strength, you may want to examine it in more detail.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Aurobindo Pharma Financials
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 2,4602,8942,6642,6482,3643,484
    Operating Expenses Qtr Cr 1,9612,1192,2102,1241,9682,856
    Operating Profit Qtr Cr 499775482545422692
    Depreciation Qtr Cr 6765646660115
    Interest Qtr Cr 515361373249
    Tax Qtr Cr 1172016313090171
    Net Profit Qtr Cr 329579624416336645
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 11,26213,226
    Operating Expenses Annual Cr 8,42211,061
    Operating Profit Annual in Cr 2,2241,731
    Depreciation Cr 255435
    Interest Annual Cr 183115
    Tax Annual Cr 503384
    Net Profit Annual Cr 1,9541,230
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 1,7151,821
    Cash from Investing Activity Annual Cr -160-3,460
    Cash from Financing Annual Activity Cr -1,8371,719
    Net Cash Flow Annual Cr -28281
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 19,72317,914
    Fixed Assets Annual Cr 2,5523,927
    Total Non Current Assets Annual Cr 17,91515,210
    Total Current Assets Annual Cr 7,2399,724
    Total Assets Annual Cr 25,15424,934
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 337306
    ROE Annual % 107
    ROCE Annual % 139
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2717
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 7,5677,5807,2717,1516,7916,379
    Operating Expenses Qtr Cr 5,9475,9075,7505,8465,6995,471
    Operating Profit Qtr Cr 1,6201,6731,6011,3731,1511,002
    Depreciation Qtr Cr 404354423418327346
    Interest Qtr Cr 1118976685756
    Tax Qtr Cr 406323322324242224
    Net Profit Qtr Cr 919909936757571506
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 29,55925,146
    Operating Expenses Annual Cr 23,15921,137
    Operating Profit Annual in Cr 5,8433,719
    Depreciation Cr 1,5221,245
    Interest Annual Cr 290140
    Tax Annual Cr 1,211685
    Net Profit Annual Cr 3,1731,928
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 2,4352,387
    Cash from Investing Activity Annual Cr -4,256-3,978
    Cash from Financing Annual Activity Cr 8001,814
    Net Cash Flow Annual Cr -1,021223
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 29,84326,840
    Fixed Assets Annual Cr 17,76615,818
    Total Non Current Assets Annual Cr 20,86618,344
    Total Current Assets Annual Cr 24,20621,546
    Total Assets Annual Cr 45,07239,890
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 509458
    ROE Annual % 117
    ROCE Annual % 1510
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2216
    Invest in Aurobindo Pharma

    Aurobindo Pharma Technicals

    EMA & SMA

    Current Price
    ₹1,552.45
    -11.55 (-0.74%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹1,532.61
    • 50 Day
    • ₹1,462.18
    • 100 Day
    • ₹1,361.39
    • 200 Day
    • ₹1,220.72
    • 20 Day
    • ₹1,544.70
    • 50 Day
    • ₹1,462.20
    • 100 Day
    • ₹1,332.62
    • 200 Day
    • ₹1,200.29

    Aurobindo Pharma Resistance and Support

    PIVOT
    ₹1,556.6
    Resistance
    First Resistance 1,564.15
    Second Resistance 1,575.85
    Third Resistance 1,583.40
    RSI 59.72
    MFI 44.78
    MACD Single Line 29.80
    MACD 24.61
    Support
    First Support 1,544.90
    Second Support 1,537.35
    Third Supoort 1,525.65

    Aurobindo Pharma Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 588,865 36,874,726 62.62
    Week 1,740,620 86,717,678 49.82
    1 Month 1,213,637 64,783,950 53.38
    6 Month 1,623,205 78,855,316 48.58

    Aurobindo Pharma Result Highlights

    Aurobindo Pharma Synopsis

    NSE-Medical-Generic Drugs

    Aurobindo Pharma is involved in the business activities of Manufacture of other pharmaceutical and botanical products like hina powder etc.. Company’s Total Operating Revenue is Rs. 10645.64 Cr. and Equity Capital is Rs. 58.59 Cr. for the Year ended 31/03/2024. Aurobindo Pharma Ltd. is a Public Limited Listed company incorporated on 26/12/1986 and has its registered office in the State of Telangana, India. Company’s Corporate Identification Number(CIN) is L24239TG1986PLC015190 and registration number is 015190.
    Market Cap 91,641
    Sales 10,715
    Shares in Float 28.12
    No of funds 726
    Yield 0.29
    Book Value 4.65
    U/D Vol ratio 2.1
    LTDebt / Equity
    Alpha 0.16
    Beta 0.69

    Aurobindo Pharma Shareholding Pattern

    Owner NameJun-24Mar-24Dec-23Sep-23
    Promoters 51.8%51.83%51.83%51.83%
    Mutual Funds 19.17%17.83%14.7%11.27%
    Insurance Companies 5.19%5.03%5.53%6.67%
    Foreign Portfolio Investors 16.73%18.01%20.72%22.45%
    Financial Institutions/ Banks
    Individual Investors 5.47%5.51%5.65%6.16%
    Others 1.64%1.79%1.57%1.62%

    Aurobindo Pharma Management

    Name Designation
    Mr. M Ramasubramanian Kumar Chairman & Ind.Dire (Non-Exe)
    Mr. K Nithyananda Reddy Vice Chairman & Mng.Director
    Mr. M Madan Mohan Reddy Whole Time Director
    Mr. P V Ramprasad Reddy Non Executive Director
    Dr. Satakarni Makkapati Non Executive Director
    Mr. P Sarath Chandra Reddy Non Executive Director
    Mr. Girish P Vanvari Independent Director
    Mrs. Savita Mahajan Independent Director
    Mr. Santanu Mukherjee Independent Director
    Dr. Deepali Pant Joshi Independent Director

    Aurobindo Pharma Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Aurobindo Pharma Corporate Action

    Date Purpose Remarks
    2024-08-10 Quarterly Results
    2024-07-18 Buy Back of Shares To consider buyback for equity shares per share(125%)Interim Dividend
    2024-05-25 Audited Results
    2024-02-10 Quarterly Results & Interim Dividend
    2023-11-09 Quarterly Results & Interim Dividend
    Date Purpose Remarks
    2024-02-20 INTERIM Rs.1.50 per share(150%)Second Interim Dividend
    2023-11-20 INTERIM Rs.3.00 per share(300%)First Interim Dividend
    2023-02-17 INTERIM Rs.3.00 per share(300%)Interim Dividend
    2022-06-07 INTERIM Rs.4.50 per share (450%) Fourth Interim Dividend
    2022-02-21 INTERIM Rs.1.50 per share(150%)Third Interim Dividend

    Aurobindo Pharma MF Shareholding

    Name Amount(cr)
    HDFC Balanced Advantage Fund Growth 95,391
    HDFC Mid-Cap Opportunities Fund Growth 75,382
    ICICI Prudential Bluechip Fund Growth 64,223
    ICICI Prudential Balanced Advantage Fund Growth 61,103
    Kotak Equity Arbitrage Fund Growth 53,423

    Aurobindo Pharma FAQs

    What is Share Price of Aurobindo Pharma ?

    Aurobindo Pharma share price is ₹1,552 As on 18 September, 2024 | 02:33

    What is the Market Cap of Aurobindo Pharma ?

    The Market Cap of Aurobindo Pharma is ₹90964 Cr As on 18 September, 2024 | 02:33

    What is the P/E ratio of Aurobindo Pharma ?

    The P/E ratio of Aurobindo Pharma is 25.8 As on 18 September, 2024 | 02:33

    What is the PB ratio of Aurobindo Pharma ?

    The PB ratio of Aurobindo Pharma is 3 As on 18 September, 2024 | 02:33

    Is it a good time to invest in Aurobindo Pharma?

    Aurobindo Pharma has an operating revenue of Rs.24,010.31 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 30% is great. Many brokers and analysts have recommended 'Buy' on the stock.

    How many times have Aurobindo Pharma given dividends since 2000?

    Aurobindo Pharma Ltd. has declared 40 dividends since May 10, 2000.

    What is the stock price CAGR of Aurobindo Pharma?

    The stock price CAGR of Aurobindo Pharma for 10 Years is 30%, 5 Years is 0%, 3 Years is -3%, 1 Year is -25%.

    What is the ROE of Aurobindo Pharma?

    Aurobindo Pharma has an ROE of 24% which is exceptional.

    What is Aurobindo Pharma’s debt to equity?

    Aurobindo Pharma has a reasonable debt to equity of 1%, which signals a healthy balance sheet.

    Q2FY23
    Open Free Demat Account

    Be a part of 5paisa community - The first listed discount broker of India.

    +91
     
    footer_form

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 29/07/2024 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

    Email: support@5paisa.com

    Support Desk Helpline: 8976689766

    ©2024, 5Paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.